Nkar­ta drops an­oth­er can­cer pro­gram as it leans in­to au­toim­mune dis­ease

Nkar­ta is punt­ing de­vel­op­ment of a nat­ur­al killer cell ther­a­py in can­cer to fo­cus in­stead on the same can­di­date’s prospects in au­toim­mune dis­ease.

The biotech …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER